VentriPoint Diagnostics Announces the Committee Membership of its Newly Elected Directors

Published: Mar 28, 2008

SEATTLE, March 28 /PRNewswire-FirstCall/ -- VentriPoint(TM) Diagnostics Ltd. today announced the board committee memberships and chair responsibilities of its newly elected directors, Joseph Ashley, Treuman Katz, Eldon Smith, M.D., Udo Henseler, Ph.D., and Danny Dalla-Longa.

VentriPoint's Audit committee will be chaired by Henseler and comprised of Katz and Dalla-Longa. The Compensation, Nominating and Corporate Governance Committee will be chaired by Dalla-Longa and comprised of Katz, Smith and Henseler. Ashley will serve as chairman of the board. Each director has experience in biotechnology and/or with start-up companies, and will hold office until the next annual meeting of shareholders.

"Our board members have developed and launched 18 medical diagnostic products between them and have relationships at nearly all of our targeted customer sites," said Edward Garth, VentriPoint CFO. "We are excited to apply this exceptional experience to the development of our diagnostic tools, which integrate with existing medical imaging systems to deliver rapid, accurate and inexpensive heart measurements that are critical but unavailable. Having worked with Joe in prior endeavors, I am excited to have the opportunity to once again support him as he builds VentriPoint."

Ashley, chairman of the board, is president and CEO of VentriPoint Diagnostics. He has successfully led the development of numerous companies in the biomedical and diagnostics industries, including Beckman Instruments Inc., which grew into a $450 million industry leader and was acquired by SmithKline. Ashley is also chairman of the board for Copernicus Therapeutics and a member of the board of directors for Geospeza Inc. and Sound Pharmaceuticals Inc.

Katz, member of the Audit Committee and the Compensation, Nominating and Corporate Governance Committee, is currently the chair of the Washington State Board of Health and the previous president and CEO of Children's Hospital and Regional Medical Center in Seattle. In this role he led strategic planning that resulted in the creation and establishment of Child Health Organization, a national venture of 42 hospital organizations. He is also a trustee of Bastyr University in Seattle, a board member of the American Heart Association and an advisory committee member of the University of Washington School of Nursing.

Smith, member of the Compensation, Nominating and Corporate Governance Committee, is the recipient of the 2005 Canadian Medical Association Medal of Service and has published more than 250 papers and book chapters. He was instrumental in the establishment of the Libin Cardiovascular Institute of Alberta for which he currently serves as its chair of the Strategic Advisory Board. Smith is a retired clinician and has been the chair of the Canadian Heart Health Strategy and Action Plan, an initiative of the Government of Canada.

Henseler, chairman of the Audit Committee and member of the Compensation, Nominating and Corporate Governance Committee, is president of Management Services International, providing CEO and CFO services, and was the chairman and CEO of eGene Inc. through its acquisition. He is also currently a board member for Spire Corporation and Tutogen Inc.

Dalla-Longa, chairman of the Compensation, Nominating and Corporate Governance Committee and member of the Audit Committee and the sole returning director, is a vice president, Corporate Finance and co-founder of i3 Capital Partners, a Canadian merchant bank focused on the energy and technology industries. Prior thereto Dalla-Longa was vice president, Corporate Finance at Rampart Securities and previously a corporate finance executive in the brokerage industry and a partner with the international accounting firm, KPMG.

About VentriPoint Diagnostics

VentriPoint is a clinical diagnostic company based in Seattle that commenced operations in January 2005 with a view to commercializing innovative and patented imaging technologies developed by the University of Washington (the "Technology"). Applying this Technology, VentriPoint is attempting to develop a breakthrough diagnostic tool for the rapid and cost effective measurement of a heart's volume and ventricular ejection fraction (heart function), which Technology, together with its associated online service, will be extendable to a variety of heart related disease states.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

CONTACT: Tracey Milani,, or Ian Stone,, both of Russo Partners LLC for VentriPoint,
+1-619-814-3510; or Edward Garth, Chief Financial Officer, VentriPoint
Diagnostics Ltd., +1-206-283-0221, Facsimile, +1-206-283-2309

Back to news